Inogen Inc. Files Q1 2025 10-Q
Ticker: INGN · Form: 10-Q · Filed: May 8, 2025 · CIK: 1294133
| Field | Detail |
|---|---|
| Company | Inogen Inc (INGN) |
| Form Type | 10-Q |
| Filed Date | May 8, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, healthcare
TL;DR
Inogen's Q1 2025 10-Q is in, check equipment & R&D spend vs last year.
AI Summary
Inogen Inc. filed its 10-Q for the period ending March 31, 2025, reporting on its financial performance. The filing details various financial statement items, including equipment, employee stock, and research and development expenses for the first quarter of 2025, comparing them to the same period in 2024.
Why It Matters
This filing provides investors with a quarterly update on Inogen's financial health and operational performance, crucial for understanding the company's trajectory in the medical device sector.
Risk Assessment
Risk Level: medium — The filing is a standard quarterly report, but the company operates in the healthcare sector which can have regulatory and market risks.
Key Numbers
- Q1 2025 — Reporting Period (First quarter financial performance)
- Q1 2024 — Prior Year Period (Comparison for financial performance)
Key Players & Entities
- Inogen Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of the reporting period
- 20250508 (date) — Filing date
- GOLETA, CA (location) — Company headquarters
FAQ
What were Inogen's total revenues for the first quarter of 2025?
The provided text does not contain specific revenue figures for Q1 2025.
How did Inogen's research and development expenses change from Q1 2024 to Q1 2025?
The filing indicates data for 'us-gaap:ResearchAndDevelopmentExpenseMember' for both Q1 2025 (2025-01-01 to 2025-03-31) and Q1 2024 (2024-01-01 to 2024-03-31), suggesting a comparison is available within the full document.
What is the fair value of Inogen's money market funds as of March 31, 2025?
The filing references 'us-gaap:MoneyMarketFundsMember' and 'us-gaap:FairValueMeasurementsRecurringMember' for March 31, 2025, indicating this information is present in the full report.
What was the net income or loss for Inogen in the first quarter of 2025?
Specific net income or loss figures are not detailed in the provided excerpt.
How many shares of common stock were outstanding as of March 31, 2025?
The excerpt mentions 'us-gaap:CommonStockMember' and '2025-03-31', implying share count data is available in the full filing.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 8, 2025 regarding Inogen Inc (INGN).